A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Latest Information Update: 17 Dec 2024
At a glance
- Drugs Lenalidomide (Primary) ; Mosunetuzumab (Primary) ; Polatuzumab vedotin (Primary) ; Tafasitamab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
Most Recent Events
- 11 May 2023 Status changed from not yet recruiting to recruiting.
- 17 Nov 2022 New trial record